Synonyms: ABX-464 | ABX464 | MMV1581032 | SPL-464
Compound class:
Synthetic organic
Comment: We obtained the chemical structure for obefazimod from WHO Proposed list 125 of July 2021. This mapped to PubChem CID 49846599, with the association to ABX464, a first-in-class, clinical-stage, oral small molecule immunomodulator [2]. ABX464 was originally developed for antiviral potential (associated via ChEMBL to the Medicines for Malaria Venture (MMV) compound MMV1581032), but was redeployed for chronic inflammatory diseases because of its potent anti-inflammatory effects in preclinical testing. ABX464 is reported to bind to the RNA cap-binding complex, which modulates both viral and cellular RNA biogenesis [1].
|
|
Bioactivity Comments |
In mammalian systems ABX464 enhances production of anti-inflammatory miR-124 [2]. |